Emixustat and lampalizumab: Potential therapeutic options for geographic atrophy

Loren S. Jack; Mohammad Ali Sadiq; Diana V. Do; Quan Dong Nguyen

doi:10.1159/000438954

Emixustat and lampalizumab: Potential therapeutic options for geographic atrophy

Loren S. Jack, Mohammad Ali Sadiq, Diana V. Do, Quan Dong Nguyen

School of Medicine

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Two novel classes of medications are currently under extensive investigation for the treatment of dry age-related macular degeneration (AMD). Emixustat, an orally administered visual cycle inhibitor, and lampalizumab, an intravitreally administered monoclonal body directed against complement factor D, have shown promise in phase 2 clinical trials in the treatment of nonneovascular (dry) AMD. Lampalizumab is currently being evaluated in a large, multicenter, phase 3 clinical trial for dry AMD - geographic atrophy.

Original language	English (US)
Pages (from-to)	302-309
Number of pages	8
Journal	Developments in ophthalmology
Volume	55
DOIs	https://doi.org/10.1159/000438954
State	Published - 2015

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1159/000438954

Cite this

@article{a4586d25036e46e58cf158024548a04f,

title = "Emixustat and lampalizumab: Potential therapeutic options for geographic atrophy",

abstract = "Two novel classes of medications are currently under extensive investigation for the treatment of dry age-related macular degeneration (AMD). Emixustat, an orally administered visual cycle inhibitor, and lampalizumab, an intravitreally administered monoclonal body directed against complement factor D, have shown promise in phase 2 clinical trials in the treatment of nonneovascular (dry) AMD. Lampalizumab is currently being evaluated in a large, multicenter, phase 3 clinical trial for dry AMD - geographic atrophy.",

author = "Jack, {Loren S.} and Sadiq, {Mohammad Ali} and Do, {Diana V.} and Nguyen, {Quan Dong}",

note = "Publisher Copyright: {\textcopyright} 2016 S. Karger AG, Basel.",

year = "2015",

doi = "10.1159/000438954",

language = "English (US)",

volume = "55",

pages = "302--309",

journal = "Developments in ophthalmology",

issn = "0250-3751",

publisher = "S. Karger AG",

}

TY - JOUR

T1 - Emixustat and lampalizumab

T2 - Potential therapeutic options for geographic atrophy

AU - Jack, Loren S.

AU - Sadiq, Mohammad Ali

AU - Do, Diana V.

AU - Nguyen, Quan Dong

PY - 2015

Y1 - 2015

N2 - Two novel classes of medications are currently under extensive investigation for the treatment of dry age-related macular degeneration (AMD). Emixustat, an orally administered visual cycle inhibitor, and lampalizumab, an intravitreally administered monoclonal body directed against complement factor D, have shown promise in phase 2 clinical trials in the treatment of nonneovascular (dry) AMD. Lampalizumab is currently being evaluated in a large, multicenter, phase 3 clinical trial for dry AMD - geographic atrophy.

AB - Two novel classes of medications are currently under extensive investigation for the treatment of dry age-related macular degeneration (AMD). Emixustat, an orally administered visual cycle inhibitor, and lampalizumab, an intravitreally administered monoclonal body directed against complement factor D, have shown promise in phase 2 clinical trials in the treatment of nonneovascular (dry) AMD. Lampalizumab is currently being evaluated in a large, multicenter, phase 3 clinical trial for dry AMD - geographic atrophy.

UR - http://www.scopus.com/inward/record.url?scp=84947261989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947261989&partnerID=8YFLogxK

U2 - 10.1159/000438954

DO - 10.1159/000438954

M3 - Article

C2 - 26501510

AN - SCOPUS:84947261989

SN - 0250-3751

VL - 55

SP - 302

EP - 309

JO - Developments in ophthalmology

JF - Developments in ophthalmology

ER -

Emixustat and lampalizumab: Potential therapeutic options for geographic atrophy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this